Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn
Eli Lilly’s buyout of the genetic medicine developer adds to lofty big pharma spending in 2025.
Cytiva Navigating cell therapy WP 4
RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals
ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups
Viralgen and Trogenix to progress gene therapy for glioblastoma
Entering the era of prenatal gene therapies
Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
DAAN Biotherapeutics and GC Cell partner for CAR-T, CAR-NK therapies
Allogeneic cell therapies “poised for prime time” says expert
